BMI but not age and sex negatively impact on the outcome of pharmacotherapy in fibromyalgia: a systematic review
CONCLUSION: Irrespective from the pharmacological approach, a higher BMI is negatively associated with a favourable outcome in patients with fibromyalgia. The association with sex and age remains controversial.LEVEL OF EVIDENCE: I, systematic review of RCTs.PMID:33990169 | DOI:10.1080/17512433.2021.1929923 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - May 15, 2021 Category: Drugs & Pharmacology Authors: Filippo Migliorini Nicola Maffulli J örg Eschweiler Markus Tingart Arne Driessen Giorgia Colarossi Source Type: research

Obesity decreases the EC50 of epidural ropivacaine when combined with dexmedetomidine for labor analgesia
This study aims to estimate the EC50 of ropivacaine when co-administered with dexmedetomidine for epidural labor analgesia in antepartum obese and non-obese parturients.METHODS: : Sixty parturients scheduled for epidural labor analgesia were enrolled and divided into antepartum obesity (AO) and control (CON) groups, according to their body mass index at labor. Both groups received 0.5 µg/mL dexmedetomidine with ropivacaine as anesthetics. The concentration of ropivacaine was initially set at 0.125% and varied by 0.01% according to the up-and-down rule for sequential allocation. Hemodynamic parameters were monitored a...
Source: Expert Review of Clinical Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Authors: Xiaojun Chen Meng Cai Xiaofeng Lei Jin Yu Source Type: research

Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients
Expert Rev Clin Pharmacol. 2021 May 13:1-11. doi: 10.1080/17512433.2021.1925536. Online ahead of print.ABSTRACTSTRACTBackground: Psoriatic arthritis (PsA) is the musculoskeletal manifestation of psoriatic disease, an inflammatory systemic disease with a high incidence in the reproductive years. Biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) as well as 'small molecules', are increasingly used to treat subtypes of PsA. Safety concerns exist in the field of fertility for PsA patients since the literature shows discordant results toward the influence of anti-psoriatic drugs.Areas covered: This c...
Source: Expert Review of Clinical Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Authors: Rebecca Fischer-Betz Monika Østensen Source Type: research

Inhaler technique in asthma and COPD: challenges and unmet knowledge that can contribute to suboptimal use in real life
Expert Rev Clin Pharmacol. 2021 May 13. doi: 10.1080/17512433.2021.1929922. Online ahead of print.ABSTRACTIntroduction: Inhalers are the most commonly used devices for lung drug delivery in asthma and COPD. Inhaler use offers several advantages but requires the user's proper mastery. The issue of inhaler technique is very important as inhaler misuse remains common in real life regardless of the inhaler used and is associated with poor disease control.Areas covered: Across a PubMed® literature search and evaluation for English publications on inhaler use conducted up to January 2021, this narrative review analyses the k...
Source: Expert Review of Clinical Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Authors: Andrea S Melani Source Type: research

Obesity decreases the EC50 of epidural ropivacaine when combined with dexmedetomidine for labor analgesia
This study aims to estimate the EC50 of ropivacaine when co-administered with dexmedetomidine for epidural labor analgesia in antepartum obese and non-obese parturients.METHODS: : Sixty parturients scheduled for epidural labor analgesia were enrolled and divided into antepartum obesity (AO) and control (CON) groups, according to their body mass index at labor. Both groups received 0.5 µg/mL dexmedetomidine with ropivacaine as anesthetics. The concentration of ropivacaine was initially set at 0.125% and varied by 0.01% according to the up-and-down rule for sequential allocation. Hemodynamic parameters were monitored a...
Source: Expert Review of Clinical Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Authors: Xiaojun Chen Meng Cai Xiaofeng Lei Jin Yu Source Type: research

Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients
Expert Rev Clin Pharmacol. 2021 May 13:1-11. doi: 10.1080/17512433.2021.1925536. Online ahead of print.ABSTRACTSTRACTBackground: Psoriatic arthritis (PsA) is the musculoskeletal manifestation of psoriatic disease, an inflammatory systemic disease with a high incidence in the reproductive years. Biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) as well as 'small molecules', are increasingly used to treat subtypes of PsA. Safety concerns exist in the field of fertility for PsA patients since the literature shows discordant results toward the influence of anti-psoriatic drugs.Areas covered: This c...
Source: Expert Review of Clinical Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Authors: Rebecca Fischer-Betz Monika Østensen Source Type: research

Inhaler technique in asthma and COPD: challenges and unmet knowledge that can contribute to suboptimal use in real life
Expert Rev Clin Pharmacol. 2021 May 13. doi: 10.1080/17512433.2021.1929922. Online ahead of print.ABSTRACTIntroduction: Inhalers are the most commonly used devices for lung drug delivery in asthma and COPD. Inhaler use offers several advantages but requires the user's proper mastery. The issue of inhaler technique is very important as inhaler misuse remains common in real life regardless of the inhaler used and is associated with poor disease control.Areas covered: Across a PubMed® literature search and evaluation for English publications on inhaler use conducted up to January 2021, this narrative review analyses the k...
Source: Expert Review of Clinical Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Authors: Andrea S Melani Source Type: research

Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk
Expert Rev Clin Pharmacol. 2021 May 10. doi: 10.1080/17512433.2021.1925539. Online ahead of print.ABSTRACTINTRODUCTION: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies has been associated with a decrease in the frequency of cardiovascular events.AREAS COVERED: A systematic search was conducted on PubMed (MEDLINE), using the MeSH terms [Rosuvastatin] + [Ezetimibe] + [Dyslipidemia] + [treatment]. Original data from clinical trials, prospective and retrospective studies and more useful reviews were selected.EXPERT OPINION: While statins continue to be the cornerstone of management of dyslipi...
Source: Expert Review of Clinical Pharmacology - May 10, 2021 Category: Drugs & Pharmacology Authors: Vivencio Barrios Carlos Escobar Source Type: research

Treatment challenges in adult female acne and future directions
Expert Rev Clin Pharmacol. 2021 May 7. doi: 10.1080/17512433.2021.1917376. Online ahead of print.ABSTRACTINTRODUCTION: Acne is a chronic, inflammatory, and immune mediated disease of the pilosebaceous unit, highly prevalent in adolescents. However, an increasing number of adults over 25 years old with facial acne, particularly women, have been observed. It is considered a different disease when compared to acne vulgaris. Face is the mainly involved area with inflammatory lesions and more sensitive skin, pointing out the need of a holistic approach.AREAS COVERED: We performed a comprehensive literature search on PubMed data...
Source: Expert Review of Clinical Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Authors: Edileia Bagatin Marco Alexandre Dias da Rocha Thais Helena Proen çade Freitas Caroline Sousa Costa Source Type: research

Classes of drugs that target the cellular components of inflammation under clinical development for COPD
Expert Rev Clin Pharmacol. 2021 May 6. doi: 10.1080/17512433.2021.1925537. Online ahead of print.ABSTRACTINTRODUCTION: : The persistent inflammation that characterizes COPD and affects its natural course also impacting on symptoms has prompted research to find molecules that can regulate the inflammatory process but still available anti-inflammatory therapies provide little or no benefit in COPD patients. Consequently, numerous anti-inflammatory molecules that are effective in animal models of COPD have been or are being evaluated in humans.AREAS COVERED: : In this article we describe several classes of drugs that target t...
Source: Expert Review of Clinical Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Luigino Calzetta Rosa Annibale Francesco Russo Mario Cazzola Source Type: research

Treatment challenges in adult female acne and future directions
Expert Rev Clin Pharmacol. 2021 May 7. doi: 10.1080/17512433.2021.1917376. Online ahead of print.ABSTRACTINTRODUCTION: Acne is a chronic, inflammatory, and immune mediated disease of the pilosebaceous unit, highly prevalent in adolescents. However, an increasing number of adults over 25 years old with facial acne, particularly women, have been observed. It is considered a different disease when compared to acne vulgaris. Face is the mainly involved area with inflammatory lesions and more sensitive skin, pointing out the need of a holistic approach.AREAS COVERED: We performed a comprehensive literature search on PubMed data...
Source: Expert Review of Clinical Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Authors: Edileia Bagatin Marco Alexandre Dias da Rocha Thais Helena Proen çade Freitas Caroline Sousa Costa Source Type: research

Classes of drugs that target the cellular components of inflammation under clinical development for COPD
Expert Rev Clin Pharmacol. 2021 May 6. doi: 10.1080/17512433.2021.1925537. Online ahead of print.ABSTRACTINTRODUCTION: : The persistent inflammation that characterizes COPD and affects its natural course also impacting on symptoms has prompted research to find molecules that can regulate the inflammatory process but still available anti-inflammatory therapies provide little or no benefit in COPD patients. Consequently, numerous anti-inflammatory molecules that are effective in animal models of COPD have been or are being evaluated in humans.AREAS COVERED: : In this article we describe several classes of drugs that target t...
Source: Expert Review of Clinical Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Luigino Calzetta Rosa Annibale Francesco Russo Mario Cazzola Source Type: research

Treatment challenges in adult female acne and future directions
Expert Rev Clin Pharmacol. 2021 May 7. doi: 10.1080/17512433.2021.1917376. Online ahead of print.ABSTRACTINTRODUCTION: Acne is a chronic, inflammatory, and immune mediated disease of the pilosebaceous unit, highly prevalent in adolescents. However, an increasing number of adults over 25 years old with facial acne, particularly women, have been observed. It is considered a different disease when compared to acne vulgaris. Face is the mainly involved area with inflammatory lesions and more sensitive skin, pointing out the need of a holistic approach.AREAS COVERED: We performed a comprehensive literature search on PubMed data...
Source: Expert Review of Clinical Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Authors: Edileia Bagatin Marco Alexandre Dias da Rocha Thais Helena Proen çade Freitas Caroline Sousa Costa Source Type: research

Classes of drugs that target the cellular components of inflammation under clinical development for COPD
Expert Rev Clin Pharmacol. 2021 May 6. doi: 10.1080/17512433.2021.1925537. Online ahead of print.ABSTRACTINTRODUCTION: : The persistent inflammation that characterizes COPD and affects its natural course also impacting on symptoms has prompted research to find molecules that can regulate the inflammatory process but still available anti-inflammatory therapies provide little or no benefit in COPD patients. Consequently, numerous anti-inflammatory molecules that are effective in animal models of COPD have been or are being evaluated in humans.AREAS COVERED: : In this article we describe several classes of drugs that target t...
Source: Expert Review of Clinical Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Luigino Calzetta Rosa Annibale Francesco Russo Mario Cazzola Source Type: research

Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab
Expert Rev Clin Pharmacol. 2021 Apr 27:1-9. doi: 10.1080/17512433.2021.1911640. Online ahead of print.ABSTRACTAREAS COVERED: The current evidence on the role of pembrolizumab for patients with extensive SCLC is reviewed in this article. Particularly, preclinical and clinical data from phase I/II and III clinical trials, which evaluate the efficacy and toxicity of pembrolizumab for these patients, are summarized based on PubMed/MEDLINE search and relevant articles. In addition, future perspectives on the emerging role of immunotherapy for SCLC are highlighted in light of potentially useful biomarkers.EXPERT COMMENTARY: Pemb...
Source: Expert Review of Clinical Pharmacology - April 27, 2021 Category: Drugs & Pharmacology Authors: Andreas Koulouris Giannis Mountzios Source Type: research

Pharmacological control of pain during propofol injection: A systematic review and meta-analysis
CONCLUSION: Pretreatment with two different drugs, opioids and surprisingly 5 HT3 antagonists were the most effective interventions compared to placebo. Combination therapy was the most effective versus lidocaine as control.PMID:33896305 | DOI:10.1080/17512433.2021.1919084 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - April 26, 2021 Category: Drugs & Pharmacology Authors: Elham Bakhtiari Seyed Hadi Mousavi Mohammad Gharavi Fard Source Type: research

Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research

Clinical trials with plants in diabetes mellitus therapy: a systematic review
Expert Rev Clin Pharmacol. 2021 Apr 22:1-13. doi: 10.1080/17512433.2021.1917380. Online ahead of print.ABSTRACTINTRODUCTION: The chronic metabolic disorder diabetes mellitus is a fast-growing global problem with huge social, health, and economic consequences, having one of the highest morbidities and mortality rates. Prolonged use of many available medications can produce undesirable side effects. Thus, plants appear as an important source of bioactive resources for the discovery of new treatments for diabetes.AREAS COVERED: In this sense, this systematic review focused on clinical trials involving plants of National List ...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Diorge Jonatas Marmitt Mohamad Hesam Shahrajabian M árcia Inês Goettert Claudete Rempel Source Type: research

Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research

Clinical trials with plants in diabetes mellitus therapy: a systematic review
Expert Rev Clin Pharmacol. 2021 Apr 22:1-13. doi: 10.1080/17512433.2021.1917380. Online ahead of print.ABSTRACTINTRODUCTION: The chronic metabolic disorder diabetes mellitus is a fast-growing global problem with huge social, health, and economic consequences, having one of the highest morbidities and mortality rates. Prolonged use of many available medications can produce undesirable side effects. Thus, plants appear as an important source of bioactive resources for the discovery of new treatments for diabetes.AREAS COVERED: In this sense, this systematic review focused on clinical trials involving plants of National List ...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Diorge Jonatas Marmitt Mohamad Hesam Shahrajabian M árcia Inês Goettert Claudete Rempel Source Type: research

Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research

Clinical trials with plants in diabetes mellitus therapy: a systematic review
Expert Rev Clin Pharmacol. 2021 Apr 22:1-13. doi: 10.1080/17512433.2021.1917380. Online ahead of print.ABSTRACTINTRODUCTION: The chronic metabolic disorder diabetes mellitus is a fast-growing global problem with huge social, health, and economic consequences, having one of the highest morbidities and mortality rates. Prolonged use of many available medications can produce undesirable side effects. Thus, plants appear as an important source of bioactive resources for the discovery of new treatments for diabetes.AREAS COVERED: In this sense, this systematic review focused on clinical trials involving plants of National List ...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Diorge Jonatas Marmitt Mohamad Hesam Shahrajabian M árcia Inês Goettert Claudete Rempel Source Type: research

Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Expert Review of Clinical Pharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research

The effect of different contraceptive methods on the vaginal microbiome
Expert Rev Clin Pharmacol. 2021 Apr 16. doi: 10.1080/17512433.2021.1917373. Online ahead of print.ABSTRACTIntroduction: Following a historical overview, the effect of different contraceptive methods on vaginal microbiome has been reviewed and summarized.Areas covered: Effects of: combined hormonal contraceptives (oral or vaginal) and of progestin only (injectable and implantable), intrauterine devices/systems (copper- or levonorgestrel-releasing), on vaginal microbiome. In addition, mention is made of vaginal rings releasing antiviral drugs and lactic acid.Expert opinion: The vaginal microbiota (VM) is unique in that it is...
Source: Expert Review of Clinical Pharmacology - April 17, 2021 Category: Drugs & Pharmacology Authors: Carlo Bastianelli Manuela Farris Paola Bianchi Giuseppe Benagiano Source Type: research

Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients
CONCLUSIONS: It was the first time to provide valuable quantitative information for efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients.PMID:33861163 | DOI:10.1080/17512433.2021.1917381 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - April 16, 2021 Category: Drugs & Pharmacology Authors: Dong-Dong Wang Yi-Zhen Mao Su-Mei He Yang Yang Xiao Chen Source Type: research

Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials
CONCLUSIONS: Single-dose baloxavir and NAIs were superior to placebo to reduce complications in uncomplicated influenza, with 40% significant reduction in antibiotic prescription. Safety and efficacy of single-dose baloxavir was non-inferior to NAIs.PMID:33861168 | DOI:10.1080/17512433.2021.1917378 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - April 16, 2021 Category: Drugs & Pharmacology Authors: Sof ía Tejada Alexandre M Tejo Yolanda Pe ña-López Carlos G Forero Xavier Corbella Jordi Rello Source Type: research

Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain
Expert Rev Clin Pharmacol. 2021 Apr 16. doi: 10.1080/17512433.2021.1917379. Online ahead of print.ABSTRACTINTRODUCTION: : The pooled worldwide prevalence of low-back pain related presentations in primary care varies between 6.8% and 28.4% in the high-income countries rendering it a major healthcare/economy problem. To best manage this complex bio-psycho-social condition a 360-degree approach is needed, as the psycho-social components are often more important than the scant pathophysiology. Pattern analysis of cannabis users suggested that attempts to alleviate Musculo-skeletal pain is often seen as a major drive to use can...
Source: Expert Review of Clinical Pharmacology - April 16, 2021 Category: Drugs & Pharmacology Authors: Laszlo Zavori Gabor Xantus Candice Matheson Valeria A Gyarmathy Laszlo M Fazekas Peter Kanizsai Source Type: research

Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients
CONCLUSIONS: It was the first time to provide valuable quantitative information for efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients.PMID:33861163 | DOI:10.1080/17512433.2021.1917381 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - April 16, 2021 Category: Drugs & Pharmacology Authors: Dong-Dong Wang Yi-Zhen Mao Su-Mei He Yang Yang Xiao Chen Source Type: research

Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials
CONCLUSIONS: Single-dose baloxavir and NAIs were superior to placebo to reduce complications in uncomplicated influenza, with 40% significant reduction in antibiotic prescription. Safety and efficacy of single-dose baloxavir was non-inferior to NAIs.PMID:33861168 | DOI:10.1080/17512433.2021.1917378 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - April 16, 2021 Category: Drugs & Pharmacology Authors: Sof ía Tejada Alexandre M Tejo Yolanda Pe ña-López Carlos G Forero Xavier Corbella Jordi Rello Source Type: research

Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain
Expert Rev Clin Pharmacol. 2021 Apr 16. doi: 10.1080/17512433.2021.1917379. Online ahead of print.ABSTRACTINTRODUCTION: : The pooled worldwide prevalence of low-back pain related presentations in primary care varies between 6.8% and 28.4% in the high-income countries rendering it a major healthcare/economy problem. To best manage this complex bio-psycho-social condition a 360-degree approach is needed, as the psycho-social components are often more important than the scant pathophysiology. Pattern analysis of cannabis users suggested that attempts to alleviate Musculo-skeletal pain is often seen as a major drive to use can...
Source: Expert Review of Clinical Pharmacology - April 16, 2021 Category: Drugs & Pharmacology Authors: Laszlo Zavori Gabor Xantus Candice Matheson Valeria A Gyarmathy Laszlo M Fazekas Peter Kanizsai Source Type: research

Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens
Expert Rev Clin Pharmacol. 2021 Apr 14. doi: 10.1080/17512433.2021.1917375. Online ahead of print.ABSTRACTINTRODUCTION: Increasing resistance of gram-negative bacteria poses a serious threat to global health. Thus, efficacious and safe antibiotics against resistant pathogens are urgently needed. Cefiderocol, a siderophore cephalosporin, addresses this unmet need.AREAS COVERED: For this article, we screened all preclinical and clinical studies on cefiderocol published by January 2021 on PubMed. Also, regulatory documents, recent conference contributions, and selected data of antibiotic competitors are reviewed. We provide a...
Source: Expert Review of Clinical Pharmacology - April 14, 2021 Category: Drugs & Pharmacology Authors: Anselm Jorda Markus Zeitlinger Source Type: research

Population pharmacokinetics of oxcarbazepine: a systematic review
Expert Rev Clin Pharmacol. 2021 Apr 14. doi: 10.1080/17512433.2021.1917377. Online ahead of print.ABSTRACTINTRODUCTION: Oxcarbazepine is commonly used as first-line treatment for partial and generalized tonic-clonic seizures. Owing to the high pharmacokinetic variability, several population pharmacokinetic models have been developed for oxcarbazepine to explore potential covariates that affect its pharmacokinetic variation.AREAS COVERED: This review summarises the published population pharmacokinetic studies of oxcarbazepine in children and adults available in PubMed and Embase databases. The quality of the retrieved studi...
Source: Expert Review of Clinical Pharmacology - April 14, 2021 Category: Drugs & Pharmacology Authors: Yue-Ting Chen Chen-Yu Wang Yi-Wei Yin Zi-Ran Li Wei-Wei Lin Min Zhu Zheng Jiao Source Type: research

Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens
Expert Rev Clin Pharmacol. 2021 Apr 14. doi: 10.1080/17512433.2021.1917375. Online ahead of print.ABSTRACTINTRODUCTION: Increasing resistance of gram-negative bacteria poses a serious threat to global health. Thus, efficacious and safe antibiotics against resistant pathogens are urgently needed. Cefiderocol, a siderophore cephalosporin, addresses this unmet need.AREAS COVERED: For this article, we screened all preclinical and clinical studies on cefiderocol published by January 2021 on PubMed. Also, regulatory documents, recent conference contributions, and selected data of antibiotic competitors are reviewed. We provide a...
Source: Expert Review of Clinical Pharmacology - April 14, 2021 Category: Drugs & Pharmacology Authors: Anselm Jorda Markus Zeitlinger Source Type: research

Population pharmacokinetics of oxcarbazepine: a systematic review
Expert Rev Clin Pharmacol. 2021 Apr 14. doi: 10.1080/17512433.2021.1917377. Online ahead of print.ABSTRACTINTRODUCTION: Oxcarbazepine is commonly used as first-line treatment for partial and generalized tonic-clonic seizures. Owing to the high pharmacokinetic variability, several population pharmacokinetic models have been developed for oxcarbazepine to explore potential covariates that affect its pharmacokinetic variation.AREAS COVERED: This review summarises the published population pharmacokinetic studies of oxcarbazepine in children and adults available in PubMed and Embase databases. The quality of the retrieved studi...
Source: Expert Review of Clinical Pharmacology - April 14, 2021 Category: Drugs & Pharmacology Authors: Yue-Ting Chen Chen-Yu Wang Yi-Wei Yin Zi-Ran Li Wei-Wei Lin Min Zhu Zheng Jiao Source Type: research

Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights
Expert Rev Clin Pharmacol. 2021 Apr 13:1-10. doi: 10.1080/17512433.2021.1913050. Online ahead of print.ABSTRACTINTRODUCTION: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose natural course has been deeply modified thanks to the development of new therapeutic approaches. The Janus kinase inhibitors (Jakinibs) represent the newest class of drugs introduced for treating RA. Among these, Filgotinib (FIL) has been developed as Janus kinase1 (JAK1) selective inhibitor, specifically targeting key pro-inflammatory mediators in RA pathogenesis.AREAS COVERED: This narrative review provides an overview on FIL as new t...
Source: Expert Review of Clinical Pharmacology - April 13, 2021 Category: Drugs & Pharmacology Authors: Maria Gabriella Raimondo Martina Biggioggero Lavinia Agra Coletto Andreas Ramming Roberto Caporali Ennio Giulio Favalli Source Type: research